ERBB2 and neoplasm: Another strategy has been to target the drug to the tumor by attaching it to some tumor-binding moiety, e.g. a tumor-specific monoclonal antibody (MAb) such as trastuzumab used in chemotherapy for HER2-positive GC [30].